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0929-6646/Copyright ª 2015, Formosa
BY-NC-ND license (http://creativecomTinnitus is a phantom auditory perception that occurs in humans. Tinnitus, which is a distres-
sing problem affecting many people around the world, is commonly referred to as ringing in the
ears. No effective drug therapy is available for this elusive disease, although much research
work into mechanism and possible treatment is underway. As yet, there are no Food and Drug
Administration approved drugs available and the quest for a new treatment option for tinnitus
focus on important challenges in tinnitus management. A number of options have been used to
treat patients with tinnitus, but outcomes have been limited. A new, curative modality will
provide a turning point in the management of tinnitus. The purpose of this review article is
to discuss the pathophysiology, global burden, current treatment, and prevention of tinnitus,
with future prospective studies in new drug therapy for this elusive condition.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Tinnitus is defined as a perception of sound in proximity to
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means ‘to ring’.1 Approximately 15% to 20% of the world’s
population suffer from tinnitus and in 25% of the affected
population, the condition interferes with daily activity;ant to this article.
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140 S.K. Swain et al.quality of life is severely affected in 1% to 3% of cases.2 Risk
factors include hearing loss, ototoxic medication, head
injury, and depression. Tinnitus has traditionally been
considered as an otological etiology, but advances in neu-
roimaging techniques along with development of animal
models has increasingly shifted studies toward its neuro-
logical correlation.
There are two categories of tinnitus. Subjective tinnitus
is the perception of sound in the absence of an acoustic
stimulus and is heard only by the sufferers, whereas
objective tinnitus is the generation of the sound near the
ear that can be heard by the examiner using the stetho-
scope.3 Subjective tinnitus is more common and occurs with
almost any ear disorder. Objective tinnitus is an uncommon
occurrence, usually heard by the examiner, commonly
caused by turbulent blood flow or by spontaneous con-
tractions of the muscles in the soft palate or middle ear.
The primary goal of tinnitus treatment is to improve
quality of life rather than provide an absolute cure. In pa-
tients with tinnitus, quality of life can be improved by
treating the comorbidities, such as hearing impairment,
depression, insomnia, and anxiety. Currently, the most
widely used treatment is counseling, and the best evidence
is seen with cognitive behavioral therapy. New insights into
the pathophysiology of tinnitus promote the innovative
brain-based treatment approach by targeting the neuronal
correlates of tinnitus.
Pathophysiology of tinnitus
The pathophysiology of tinnitus is one of the most contro-
versial issue in medical science. Tinnitus is associated with
several risk factors, such as prolonged noise exposure (22%
of cases), head/neck injury (17% of cases) and infections
(10% cases).4 The newer pathophysiology theory suggests
that the central nervous system is the source or generator
of tinnitus.5 Functional magnetic resonance imaging and
positron emission tomography scan of the inner ear and
brain show a loss of cochlear input by cochlear hair cell
damage or a lesion of the auditory nerve to the central
auditory system can lead to abnormal neural activity in the
auditory cortex area.6
It is now known that approximately 24% of tinnitus cases
occur due to abnormalities within the inner ear and vesti-
bulocochlear nerve, 35% originate due to abnormalities in
the acoustic pathway, and 41% cases have origin within the
supratentorial structures.7 An increase in excitation or a
decrease in inhibition may cause an excitatory-inhibitory
imbalance, lead to hyperexcitability in these regions, and
perception of the tinnitus (Figure 1). Certain neurotrans-
mitters and neuromodulators facilitate the neuronal
excitability acting over voltage gated channels, and thus
create potential pharmacological targets.8
Global burden of tinnitus
In a large epidemiological survey in Norway, 21.3% of men
and 16.2% of women reported tinnitus, among whom 4.4% of
men and 2.1% women reported high-intensity tinnitus.9
Epidemiological data show similar results not only seen in
other European countries, the United States, and Japan, butalso in low-income or middle-income countries such as Af-
rica and Asia.10 These data show that tinnitus is now a global
burden. Increasing age, sensorineural hearing loss, and male
sex have been seen as the most relevant risk factors for the
origin of tinnitus.11 Because of the increase in professional
and leisure noise with demographic development, the
prevalence of tinnitus is expected to increase.12 In addition,
it is a frequent aftereffect of modern warfare.13Treatment of tinnitus
Because of the many etiologies and complex pathophysi-
ology of tinnitus, definitive treatment is yet to be devel-
oped. Before treatment can be attempted, proper clinical
assessment including a detailed history, measurement of
the amount of hearing loss, quantification of tinnitus
severity (Figure 2), and identification of etiological factors
(Figure 3), associated symptoms, and comorbidities should
be performed.
Intravenous lidocaine seems to be effective in some
patients with tinnitus; however, the effect is transient and
the route of administration not practical in a clinical setting
of a chronic condition; therefore, its additional side effects
forced its withdrawal from use.14 Antidepressants are
commonly prescribed to treat patients because tinnitus is
often associated with depressive disorders. Of all antide-
pressants, the tricyclic group of drugs is used because of
their analgesic effect.15 This property of tricyclic antide-
pressant is helpful in view of the proposed etiological
similarities between tinnitus and neuropathic pain.16
Nortriptyline is effective in decreasing the loudness and
severity of the tinnitus but is less effective in nondepressed
patients.17 Treatment of tinnitus with benzodiazepines has
some benefit. However, due to its adverse effect on regular
intake, their routine use cannot be recommended for
treatment of tinnitus.18 Glutamate is an excitatory neuro-
transmitter in the auditory system. However, various
glutamate antagonists such as memantine, flutirpine, and
neremexane have not been beneficial in patients with
tinnitus.19 Investigations into the effectiveness of gluta-
mate antagonists continue. Treatment with intravenous
caroverine, an antagonist of non-N-methyl-D-aspartic acid
(NMDA) and NMDA receptors, has been studied, with con-
tradictory outcomes.20 Sometimes patients with tinnitus
have depression or anxiety associated with elevated serum
serotonin. Serotonin and g-aminobutyric acid receptors are
present in the auditory system and have been thought to
play a role in some cases. Anxiolytic (e.g., diazepam) an-
tidepressants (e.g., amitriptyline), anticonvulsants (e.g.,
clonazepam), diuretics, and antihistamines (e.g., dex-
chlorpheniramine maleate) all have shown inconsistent and
inconclusive results.2 Ginkgo biloba is one of the popular
complementary and alternative medicine used by many
physicians, but a large trial failed to yield definitive
success.21
Although betahistine improves cochlear blood flow,
there is no evidence suggesting that it is effective in the
tinnitus associated with Me´nie`re disease or in other types of
tinnitus.22 Melatonin can help in patients with insomnia
associated with tinnitus.23 It has been suggested that di-
etary intake of vitamin B, zinc, and magnesium can helpful
Figure 1 A schematic diagram showing pathophysiology of tinnitus.
Tinnitus and its current treatment 141for tinnitus.19 There are multiple nonpharmacological
treatment options available, such as tinnitus retraining
therapy (TRT), masking, amplification, and limiting
inducing agents and environmental factors. Masking usually
covers or partially covers the tinnitus with an external
sound. The sound used for masking is usually less bother-
some than the tinnitus. Masking devices are made to
generate low-level sounds that decrease the perception of
tinnitus. However, in some patients worsening of their
tinnitus occurs.24No
No
Yes
Is Ɵnnitus  disturbing 
you?
Is your Ɵnnitus making 
a major negaƟve 
consequences on your 
daily life?
Are you able to 
work?
Can you do your 
housework?
Can you take care of 
your
family?
No
Yes
Yes
Figure 2 QuantificationTRT includes counseling and sound generator therapy
and is more effective than masking.25 The concept behind
TRT is bypassing or overriding abnormal auditory cortex
neural pathways, the pathophysiology postulated to drive
tinnitus. The auditory neural pathways play a vital role in
tinnitus and also induce habituation to the tinnitus signal.26
The aim of this therapy is to reach a stage in which patients
with tinnitus are unaware of their condition unless they
consciously focus on it. Here, the habituation is achieved by
directive counseling along with low-level noise generatedGrade I (No impairment)
Grade II (mild impairment)
mild annoyance in certain 
condiƟon like In quiet 
environment or in stressful 
condiƟon
Grade III 
Permanent annoyance with 
disturbances in private and 
professional areas
Grade IV 
Severe impairment severe 
disturbances in private and 
working life, unable to work
of tinnitus severity.
Figure 3 Identification of etiological factors from clinical presentations with its treatment options.
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cant improvement has been seen in up to 80% of the cases
but no well-controlled studies have been reported. The
long-term effect of TRT is not well known, and outcome
evaluation can take up to 1 to 2 years.24
Biofeedback or relaxation techniques help patients with
tinnitus control certain autonomic functions of the body.
The aim of the biofeedback technique is to manage the
tinnitus-associated distress by changing the patient’s re-
action to it, leading to reductions in tinnitus.27 Cognitive
behavioral therapy is usually done by a psychologist. The
patient with tinnitus is trained to cope with the condition,
and this therapy attempts to change the way the patient
thinks about his or her tinnitus. By decreasing the negative
thoughts for tinnitus, its annoyance can be minimized. This
technique alters the psychological response to tinnitus by
identifying and reinforcing coping strategies, and relaxa-
tion and distraction techniques. Large studies reported
benefit in many patients in reducing tinnitus-related
distress, but not much help in decreasing the loudness of
the tinnitus.27
Hearing aids are often used by patients with tinnitus and
hearing loss to compensate for the absence of auditory
input in the impaired frequency range. Amplification of
sound with hearing aid is confined to the high-frequency
range and will not help in patients with complete absence
of inner ear hair cells. In patients with bilateral profoundsensorineural hearing loss and tinnitus, a significant sup-
pression of tinnitus has been reported after hearing loss
was restored by cochlear implant.28
Surgery has a small but definite role in case of tinnitus
treatment. It has a place in regard to pulsatile tinnitus
and associated specific clinical conditions such as
otosclerosis or Me´nie`re disease. Surgery for neurovascular
decompression is beneficial when blood vessels are
pressing the auditory nerve. More than 80% of patients
with bilateral profound sensorineural hearing loss have
tinnitus. A cochlear implant eliminates tinnitus in up to
86% of these patients, although 9% show worse post-
operative tinnitus.28
During management of tinnitus, assessment of hyper-
tension, lipid profiles, thyroid function tests, allergies, and
factors aggravating tinnitus such as stress, caffeine,
aspirin, and nicotine intake.29 If any of these levels or
conditions is abnormal, they should be treated before the
tinnitus. Embolization or ligation should be used to treat a
vascular anomaly such as arteriovenous malformation. The
use of hearing aids and cochlear implants to treat sensori-
neural hearing loss with cessation of offending medications
is also an important aspect of tinnitus treatment.
Acupuncture, herbal remedies such as Ginkgo biloba, ear
candling, low-power lasers, and electromagnetic stimula-
tion all have been used to treat tinnitus but with little
evidence of benefit.30 Tinnitus of “low buzz” type often
Tinnitus and its current treatment 143associated with temporomandibular joint dysfunction
(TMD) can affect the Eustachian tube and tympanic struc-
tures.31 Laser acupuncture is an innovative treatment op-
tion for TMD because it is noninvasive, results in partial or
total relief of pain, and has no complications.32
Subjective tinnitus due to stapedius myoclonus syn-
drome is rare and severely affects daily activities such as
eating, talking, and walking. It may be treated with noise
masking, anticonvulsant agents, or myotenotomy but has
very good result with the addition of botulinum toxin A.33
Drugs in the pipeline for patients with tinnitus
Neurokinin receptors are present in the inner ear, which has
a potential therapeutic target for treating tinnitus. Vesti-
pitant is an antagonist of the neurokinin-1 receptor, which
usually binds substance P.34 Vestipitant and the combina-
tion of paroxetine and vestipitant are currently under
clinical trials for treating patients with tinnitus.
A nonsterile patch (LidoPAIN TV, EpiCept) has been
developed for delivery of lidocaine applied over preaur-
icular skin. Its clinical efficacy is also under clinical trial.
Neramexane is a noncompetitive, voltage dependent
nonselective NMDA antagonist that blocks the nicotinic
cholinergic receptors present on the hair cells of the inner
ear.35 This drug is also in clinical trials for determining its
efficacy, tolerability, and safety.
Prevention
Significant loud noise, ototoxic drugs, and cytotoxic drugs
are risk factors for the development of tinnitus. These risk
factors cause damage to the cochlear hair cells by apoptosis
rather than necrosis.36 Currently, research is focused on
identifying agents that block the apoptosis. The use of
antioxidants is now an area of interest, with D-methionine
or a combination of betacarotene, vitamin C, and vitamin E
showing initial promise.37 Cochlear insult can be repaired
using stem cell therapy and gene therapy. Smoking,
excessive alcohol or caffeine intake, or central nervous
stimulant are stopped. Drugs such as aspirin should be
stopped or the alternative drug may be started after proper
counseling the patient.
Conclusion
The successful treatment of tinnitus depends on a team
comprising an otolaryngologist, audiologist, neurologist,
psychologist, and sleep or pain specialists. Even with
progress in the understanding of the pathophysiology of
tinnitus, treatment modalities still focus on minimizing
the awareness of tinnitus and its effect on quality of life
rather than a definitive cure. Although we are far away
from an exact understanding of the pathophysiology of
tinnitus, the treatment options are much more encour-
aging than a decade ago. Due to medical advancement
with molecular, biochemical, and imaging techniques,
important insights into the underlying etiology of tinnitus
have occurred. Currently, patients show improvement
with counseling, cognitive behavioral therapy, andadditional use of different sound therapy; however, many
prefer drug therapy that would lead to complete sup-
pression of tinnitus. Looking towards the future treat-
ment of tinnitus, the development of new molecular
treatment for complete cure of tinnitus will be an
important goal.
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